1. HBW Insight
  2. >>Ingredients & Safety

CIR Panel: Epidemiology Evidence Still Lacking Regarding Possible Hair Dye-Cancer Links

 
• By Eileen Francis

Potential connections between hair-dye use and cancer incidence have been just hazily sketched in epidemiological studies to date, signaling a need for more targeted, better-designed investigations, CIR’s Expert Panel says. The group finalized a related resource document at its December meeting in Washington after multiple rounds of revisions and outside expert input.    

Hair salon

The Cosmetic Ingredient Review has a vision of the optimal study needed to fill epidemiological data gaps concerning hair-dye use and cancer incidence, but for now available evidence remains inadequate to support any causal connection between the two, it says.

A draft revision of CIR’s Hair Dye Epidemiology resource document has been under consideration by the group’s Expert Panel since April

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Ingredients & Safety

More from HBW Insight

Venture Life Focuses On CHC As It Offloads CDMO

 
• By Tom Gallen

UK-based Venture Life is divesting its CDMO business and some non-core products to focus its attention on growing its consumer health operation.

New Zealand Could Become First Country To Offer Gout Drug Allopurinol OTC

 
• By David Ridley

At the second attempt, New Zealand’s Medicines Classification Committee supported the Rx-to-OTC switch of allopurinol (100mg and 300mg) for people suffering from gout by specifically trained pharmacists.

Mitigating Tariff Impacts, Kenvue Adjusts Outlook

 
• By Malcolm Spicer

“The situation has evolved considerably” since Kenvue gave its initial full-year outlook in February, “and remains quite fluid,” says president and CEO Thibaut Mongon as firm reports Q1 net sales decreasing 3.9% to $3.7bn